Outcome of pediatric oncology patients with febrile neutropenia after introduction of a standard operating procedure for time-to-antibiotic therapy in a children's cancer center

• Conditions: fever in neutropenia; D70; Agranulocytosis

• Registration Number: DRKS00029542
• Lead Sponsor: Zentrum für Kinder- und Jugendmedizin des Universitätsklinikums Freiburg,Klink für pädiatrische Hämatologie und Onkologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-07-06
• Study Completion: 2023-12-15
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 117

Inclusion Criteria

Pediatric oncology patients treated by home or external clinic/physician without prior treatment with fever in neutropenia (ANC <500) and/or in reduced general condition and/or with clinical signs of SIRS after chemotherapy in the pediatric emergency department or in the Oncology Outpatient Clinic of the Center for Pediatric and Adolescent Medicine from May 2019 to May 2021 and then admitted as inpatients
Consent for inclusion in the Hilda Biobank with use of linked clinical data.

Exclusion Criteria

Patients with prior antibiotic treatment, fever without neutropenia or without change in general condition or signs of SIRS.
Lack of consent for inclusion in the Hilda Biobank.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To determine the effect of an introduction of a standard operating procedure (SOP) for the treatment of FN on the TTA at the University Childrens Hospital of Freiburg. To assess the impact of the implemented SOP on the clinical course of FN in paediatric cancer patients presenting with FN.